Panbela Therapeutics

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 7 full-time employees. The company went IPO on 2014-07-29. The firm is developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company’s lead candidates are ivospemin (SBP-101), for which it has licensed the worldwide rights from the University of Florida Research Foundation, Inc., Flynpovi, a combination of eflornithine (CPP-1X) and sulindac and eflornithine (CPP-1X), alone in tablet or sachet form. The company has licensed rights from the Arizona Board of Regents of the University of Arizona to commercialize Flynpovi. Additionally, eflornithine is being evaluated with high dose testosterone and enzalutamide in metastatic castration-resistant prostate cancer in a phase II trial. The firm is engaged in over two sponsored research agreements to evaluate the polyamines individually and combined for various diseases.